-

Tivic to Reconvene Annual Meeting of Stockholders June 14, 2023

Tivic urges shareholders of record as of April 13, 2023, to vote their shares.

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for and convened on Tuesday, June 6, 2023, was partially adjourned to Wednesday, June 14, 2023, at 1:00 p.m. Pacific Standard Time. The record date for determining stockholders eligible to vote at the Annual Meeting will remain the close of business on April 13, 2023.

Jennifer Ernst, CEO of Tivic Health, explained, “We are very encouraged by the percentage of stockholders who voted in support of key proposals on the ballot. However, due to limited proxy representation, we still need additional votes in order to obtain approval of key measures. I cannot understate the importance of shareholder representation, which is why our Board unanimously voted to reconvene on June 14 in the interest of soliciting further shareholder support.”

Tivic strongly encourages its stockholders to vote.

Stockholders as of the close of business on April 13, 2023, the record date for the Annual Meeting, who have not yet voted are encouraged to vote over the Internet at www.virtualshareholdermeeting.com/TIVC2023. Stockholders needing assistance voting or have questions may contact the Company at ir@tivichealth.com.

About Tivic

Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic’s first commercial product, ClearUP, is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information, visit http://tivichealth.com @TivicHealth

Forward-Looking Statements

This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: market, economic and other conditions; supply chain constraints; macroeconomic factors, including inflation; the company’s ability to raise additional capital on favorable terms; changes in regulatory requirements; and unexpected costs, charges or expenses that reduce Tivic’s capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic’s actual results to differ from those contained in the forward-looking statements, see Tivic’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 31, 2023, under the heading “Risk Factors,” as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.

Contacts

Investor Contact:
Hanover International, Inc.
ir@tivichealth.com

Tivic Health Systems, Inc.

NASDAQ:TIVC

Release Versions

Contacts

Investor Contact:
Hanover International, Inc.
ir@tivichealth.com

More News From Tivic Health Systems, Inc.

Tivic Expands Intellectual Property Portfolio

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced it is expanding its intellectual property portfolio with the recent filing of two additional patent applications with the United States Patent and Trademark Office. The first application applies to Tivic’s TLR5 agonist portfolio, which includes Entolimod and Entolasta. The patent titled “Immunomodulatory Pathway Modifying Agents and Uses of Same for Cancer Therapy” r...

Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 230582 Webcast Link https://www.webcaster5.com/Webcast/Page/2865/53145 About Tivic Health Systems, Inc. T...

Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to...
Back to Newsroom